BioInvent International AB, publicly traded on Nasdaq Stockholm with the ticker symbol BINV, is a biotech company specializing in the exploration and development of innovative immune-modulatory antibodies for cancer immunotherapy. The company recently achieved a significant milestone by initiating the enrollment of the first patient in its Phase 1/2a trial for the monoclonal antibody BI-1910. This marks the commencement of BioInvent's second anti-tumor necrosis factor receptor 2 (TNFR2) program in clinical development.

The Phase 1/2a clinical trial is set to take place across the United States and Europe and will employ an adaptive design for dose escalation. Initially, the trial will enroll patients with various solid cancer entities, focusing on evaluating BI-1910 as a single agent. Subsequently, a dose escalation phase will be introduced, assessing the combination of BI-1910 with pembrolizumab. There are also plans for exploratory expansion cohorts, specifically targeting hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC).

Martin Welschof, BioInvent's CEO, underscored the significance of this milestone, highlighting that BI-1910 represents the company's fifth drug candidate to enter clinical development. He also mentioned the progress of their first anti-TNFR2 antibody, BI-1808, which is currently undergoing a Phase 1/2a trial. Welschof emphasized the differentiated approach offered by BI-1910 and the company's deep understanding of TNFR2 biology. Both BI-1808 and BI-1910 were carefully chosen as potential best-in-class candidates from a diverse family of binders generated through BioInvent's proprietary F.I.R.S.T™ technology platform. BI-1910, with its unique agonist approach, presents a promising avenue in the ongoing quest for effective cancer treatment.

Source: bioinvent.com